Torii Gets Japan Option Rights to Verrica’s Warts Drug

August 6, 2020
Torii Pharmaceutical, a subsidiary of Japan Tobacco, has concluded an option agreement with US dermatology specialty firm Verrica Pharmaceuticals for the exclusive development and commercialization of its skin disease drug candidate VP-102 in Japan. The two companies announced the pact...read more